Skip to main content

Table 2 Comparison between baseline, 6 month and 12 month time-point measurements after anti-VEGF treatment

From: Changes in retinal and choriocapillaris density in diabetic patients receiving anti-vascular endothelial growth factor treatment using optical coherence tomography angiography

  Baseline (n = 19) 6 month
(n = 17)
12 month
(n = 16)
Overall comparison p-value Baseline-6 month p-value 6 month–12 month p-value
FAZ area mm2
(SD)
0.307
(± 0.133)
0.3
(± 0.1)
0.313
(± 0.1)
0.6 0.5* 0.10*
Perimeter mm2
(SD)
2.415
(± 0.692)
2.4
(± 0.5)
2.394
(± 0.4)
0.7 0.9* 0.3*
Choroid thickness µm
(SD)
335.9
(± 39.1)
347.2
(3 ± 8.1)
336.8
(± 44.6)
0.7 0.4* 0.3
Choriocapillaris whole image density %
(SD)
62.6
(± 6.1)
63.4
(± 6.4)
63.9
(± 6.9)
0.9 0.7* 0.5*
Choriocapillaris foveal area density %
(SD)
61.2
(± 7.4)
60.6
(± 8.8)
59.1
(± 7.9)
0.85 0.8 0.3*
Choriocapillaris parafoveal area density %
(SD)
61.9
(± 6.6)
63.2
(± 6.6)
64.1
(± 7.3)
0.9 0.5* 0.7*
Retinal whole image density %
(SD)
46.9
(± 5.1)
45.3
(± 5.2)
45.7
(± 5.0)
0.5 0.4* 0.5*
Retinal foveal area density %
(SD)
27.6
(± 5.9)
25.2
(± 6.9)
25.0
(± 6.8)
0.2 0.3* 0.07*
Retinal parafoveal area density %
(SD)
49.0
(± 5.6)
47.5
(± 5.7)
48
(± 4.9)
0.6 0.1 0.6*
CST µm
(SD)
397.1
(± 93.2)
300.4
(± 67.8)
294.2
(± 71.5)
0.005 0.001* 0.7*
Visual acuity ETDRS
(SD)
69.6
(± 7.9)
72.2
(± 7.9)
73.9
(± 7.2)
0.3 0.2* 0.3*
  1. Italic values indicate the statistical significance
  2. SD standard deviation, FAZ foveal avascular zone, CST central subfield thickness, ETDRS early treatment diabetic retinopathy study
  3. * T-test, Mann–Whitney, One-way ANOVA